{"id":62007,"date":"2026-03-31T19:55:24","date_gmt":"2026-03-31T11:55:24","guid":{"rendered":"https:\/\/flcube.com\/?p=62007"},"modified":"2026-03-31T19:55:25","modified_gmt":"2026-03-31T11:55:25","slug":"luye-pharma-subsidiary-boan-bio-reports-8-1-revenue-growth-driven-by-multiple-product-approvals-in-2025","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62007","title":{"rendered":"Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025"},"content":{"rendered":"\n<p><strong>Shandong Boan Biotechnology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6955:HKG\">HKG: 6955<\/a>), a controlling subsidiary of <strong>Luye Pharma Group<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2186:HKG\">HKG: 2186<\/a>), has released its <strong>2025 financial results<\/strong>, reporting <strong>8.1% year-over-year revenue growth<\/strong> to <strong>RMB 785 million<\/strong> (USD 114 million) alongside multiple regulatory approvals for its biologic portfolio across diabetes, ophthalmology, and oncology indications.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2025 Result<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Annual Revenue<\/strong><\/td><td>RMB 785M (USD 114M)<\/td><td>+8.1%<\/td><\/tr><tr><td><strong>Total Comprehensive Income<\/strong><\/td><td>RMB 6.944M (USD 101M)<\/td><td>N\/A<\/td><\/tr><tr><td><strong>Cash Reserves<\/strong><\/td><td>RMB 1.13B (USD 163M)<\/td><td>N\/A<\/td><\/tr><tr><td><strong>Reporting Period<\/strong><\/td><td>Full Year 2025<\/td><td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-approvals-timeline\">Regulatory Approvals Timeline<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-mainland-china-approvals\">Mainland China Approvals<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>August 2025:<\/strong> <strong>Boyouping (dulaglutide)<\/strong> approved for blood glucose control in adult patients with type 2 diabetes mellitus<\/li>\n\n\n\n<li><strong>November 2025:<\/strong> <strong>Boyoujing (aflibercept intravitreal injection)<\/strong> approved for:<\/li>\n\n\n\n<li>Neovascular (wet) age-related macular degeneration (nAMD)<\/li>\n\n\n\n<li>Diabetic macular edema (DME)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-macau-approvals\">Macau Approvals<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>May 2025:<\/strong> Three biosimilars approved for marketing:<\/li>\n\n\n\n<li><strong>Boyounuo<\/strong> (bevacizumab biosimilar)<\/li>\n\n\n\n<li><strong>Boyoubei<\/strong> (denosumab biosimilar)<\/li>\n\n\n\n<li><strong>Boluojia<\/strong> (denosumab biosimilar)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-portfolio-analysis\">Product Portfolio Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Area<\/th><th>Product<\/th><th>Reference Drug<\/th><th>Market Opportunity<\/th><\/tr><\/thead><tbody><tr><td><strong>Diabetes<\/strong><\/td><td>Boyouping (dulaglutide)<\/td><td>Trulicity (Eli Lilly)<\/td><td>USD 7+ billion global GLP-1 market<\/td><\/tr><tr><td><strong>Ophthalmology<\/strong><\/td><td>Boyoujing (aflibercept)<\/td><td>Eylea (Regeneron)<\/td><td>USD 9+ billion anti-VEGF eye disease market<\/td><\/tr><tr><td><strong>Oncology<\/strong><\/td><td>Boyounuo (bevacizumab)<\/td><td>Avastin (Roche)<\/td><td>Mature but substantial biosimilar opportunity<\/td><\/tr><tr><td><strong>Bone Health<\/strong><\/td><td>Boyoubei\/Boluojia (denosumab)<\/td><td>Prolia\/Xgeva (Amgen)<\/td><td>Growing osteoporosis and oncology markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The diversified approval strategy spans high-growth therapeutic areas with significant commercial potential in both domestic and international markets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-business-impact\">Strategic Business Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Revenue Diversification<\/strong><\/td><td>Multiple product launches reduce dependency on single therapeutic area<\/td><\/tr><tr><td><strong>Market Access<\/strong><\/td><td>Mainland China approvals provide access to world&#8217;s second-largest pharmaceutical market<\/td><\/tr><tr><td><strong>Biosimilar Leadership<\/strong><\/td><td>Three simultaneous biosimilar approvals demonstrate robust development capabilities<\/td><\/tr><tr><td><strong>Financial Strength<\/strong><\/td><td>Strong cash position (RMB 1.13B) supports commercial launch activities and pipeline advancement<\/td><\/tr><tr><td><strong>Parent Company Synergy<\/strong><\/td><td>Integration with Luye Pharma Group provides commercial infrastructure and distribution network<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The 2025 approvals represent a strategic inflection point, transitioning Boan Bio from development-focused to commercial-stage operations across multiple high-value therapeutic categories.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-outlook-amp-competitive-positioning\">Market Outlook &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GLP-1 Market Entry:<\/strong> Boyouping positions Boan Bio in the rapidly expanding diabetes market dominated by premium-priced GLP-1 therapies<\/li>\n\n\n\n<li><strong>Ophthalmology Expansion:<\/strong> Boyoujing addresses significant unmet need in retinal diseases with limited treatment options in China<\/li>\n\n\n\n<li><strong>Biosimilar Portfolio:<\/strong> Dual denosumab biosimilars suggest different formulations or indications, maximizing market coverage<\/li>\n\n\n\n<li><strong>Geographic Strategy:<\/strong> Macau approvals may serve as stepping stone to broader Greater China and international markets<\/li>\n\n\n\n<li><strong>Commercial Execution:<\/strong> 2026-2027 expected to be critical years for market penetration and revenue realization from new products<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Boan Biotechnology&#8217;s financial performance, product commercialization, and market expectations. Actual commercial outcomes may vary based on pricing negotiations, market adoption, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026033004137_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026033004137_c.\"><\/object><a id=\"wp-block-file--media-c1fdd1cb-c84e-49bf-8847-29add117cc4c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026033004137_c.pdf\">2026033004137_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026033004137_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c1fdd1cb-c84e-49bf-8847-29add117cc4c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shandong Boan Biotechnology Co., Ltd. (HKG: 6955), a controlling subsidiary of Luye Pharma Group (HKG:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":62011,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[220,27,1023,1024,219],"class_list":["post-62007","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-boan-biotechnology","tag-finanical-reports","tag-hkg-2186","tag-hkg-6955","tag-luye-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955), a controlling subsidiary of Luye Pharma Group (HKG: 2186), has released its 2025 financial results, reporting 8.1% year-over-year revenue growth to RMB 785 million (USD 114 million) alongside multiple regulatory approvals for its biologic portfolio across diabetes, ophthalmology, and oncology indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62007\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025\" \/>\n<meta property=\"og:description\" content=\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955), a controlling subsidiary of Luye Pharma Group (HKG: 2186), has released its 2025 financial results, reporting 8.1% year-over-year revenue growth to RMB 785 million (USD 114 million) alongside multiple regulatory approvals for its biologic portfolio across diabetes, ophthalmology, and oncology indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62007\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T11:55:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T11:55:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3101-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62007#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62007\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025\",\"datePublished\":\"2026-03-31T11:55:24+00:00\",\"dateModified\":\"2026-03-31T11:55:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62007\"},\"wordCount\":429,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62007#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3101-1.webp\",\"keywords\":[\"Boan Biotechnology\",\"Finanical Reports\",\"HKG: 2186\",\"HKG: 6955\",\"Luye Pharma\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62007#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62007\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62007\",\"name\":\"Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62007#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62007#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3101-1.webp\",\"datePublished\":\"2026-03-31T11:55:24+00:00\",\"dateModified\":\"2026-03-31T11:55:25+00:00\",\"description\":\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955), a controlling subsidiary of Luye Pharma Group (HKG: 2186), has released its 2025 financial results, reporting 8.1% year-over-year revenue growth to RMB 785 million (USD 114 million) alongside multiple regulatory approvals for its biologic portfolio across diabetes, ophthalmology, and oncology indications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62007#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62007\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62007#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3101-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3101-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62007#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025 - Insight, China&#039;s Pharmaceutical Industry","description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955), a controlling subsidiary of Luye Pharma Group (HKG: 2186), has released its 2025 financial results, reporting 8.1% year-over-year revenue growth to RMB 785 million (USD 114 million) alongside multiple regulatory approvals for its biologic portfolio across diabetes, ophthalmology, and oncology indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62007","og_locale":"en_US","og_type":"article","og_title":"Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025","og_description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955), a controlling subsidiary of Luye Pharma Group (HKG: 2186), has released its 2025 financial results, reporting 8.1% year-over-year revenue growth to RMB 785 million (USD 114 million) alongside multiple regulatory approvals for its biologic portfolio across diabetes, ophthalmology, and oncology indications.","og_url":"https:\/\/flcube.com\/?p=62007","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-31T11:55:24+00:00","article_modified_time":"2026-03-31T11:55:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3101-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62007#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62007"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025","datePublished":"2026-03-31T11:55:24+00:00","dateModified":"2026-03-31T11:55:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62007"},"wordCount":429,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=62007#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3101-1.webp","keywords":["Boan Biotechnology","Finanical Reports","HKG: 2186","HKG: 6955","Luye Pharma"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62007#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62007","url":"https:\/\/flcube.com\/?p=62007","name":"Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=62007#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=62007#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3101-1.webp","datePublished":"2026-03-31T11:55:24+00:00","dateModified":"2026-03-31T11:55:25+00:00","description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955), a controlling subsidiary of Luye Pharma Group (HKG: 2186), has released its 2025 financial results, reporting 8.1% year-over-year revenue growth to RMB 785 million (USD 114 million) alongside multiple regulatory approvals for its biologic portfolio across diabetes, ophthalmology, and oncology indications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62007#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62007"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=62007#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3101-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3101-1.webp","width":1080,"height":608,"caption":"Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62007#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3101-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62007"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62007\/revisions"}],"predecessor-version":[{"id":62012,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62007\/revisions\/62012"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/62011"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62007"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62007"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}